JNJ ▼ -0.0% - Johnson & Johnson
$JNJ - Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
29-SEP-2026 08:03 AM ET
Share this post
More filings for $JNJ
JNJ ▼ -0.8% - Johnson & JohnsonOct 19, 2026JNJ ▼ -0.8% - Johnson & JohnsonOct 19, 2026JNJ ▼ -0.7% - Johnson & JohnsonOct 13, 2026JNJ ▼ -0.7% - Johnson & JohnsonOct 13, 2026JNJ ▲ +0.9% - Johnson & JohnsonOct 12, 2026JNJ ▲ +0.9% - Johnson & JohnsonOct 12, 2026
View full $JNJ filing history →💬 Comments
Loading comments…
Leave a comment